3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
2
nilotinib
2
avapritinib
2
trastuzumab deruxtecan
1
talquetamab
1
pomalidomide
1
montelukast
1
lazertinib
1
larotrectinib
1
ivosidenib
1
entrectinib
1
dostarlimab
1
daratumumab
1
carfilzomib
1
asciminib
1
amivantamab
1
Thalidomide
1
TIC10 compound
1
Prednisone
1
Pemetrexed
1
Melphalan
1
Lenalidomide
1
Imatinib Mesylate
1
Diphenhydramine
1
Dexamethasone
1
Dasatinib
1
Crizotinib
1
Carboplatin
1
Bortezomib
1
Appointments and Schedules
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Has announcements
×
dostarlimab
×
Clear all
NCT02715284
2026-01-13
GARNET
Tesaro, Inc.
Phase 1
Active not recruiting
730 enrolled
3 FDA